Aerovate Therapeutics EBITDA Margin 2020-2024 | JBIO
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Aerovate Therapeutics (JBIO) over the last 10 years. The current EBITDA margin for Aerovate Therapeutics as of December 31, 2024 is .
| Aerovate Therapeutics EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.008B |
$0.000B |
|
Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
|
